首页> 美国卫生研究院文献>Elsevier Sponsored Documents >C8-substituted pyrido34-dpyrimidin-4(3H)-ones: Studies towards the identification of potent cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors compound profiling in cell-based target engagement assays
【2h】

C8-substituted pyrido34-dpyrimidin-4(3H)-ones: Studies towards the identification of potent cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors compound profiling in cell-based target engagement assays

机译:C8取代的吡啶并34-d嘧啶-4(3H)-ones:鉴定含组蛋白赖氨酸脱甲基酶4亚家族(KDM4)抑制剂的强力细胞渗透性Jumonji C结构域的研究在基于细胞的靶标中进行化合物分析参与测定

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Residues in the histone substrate binding sites that differ between the KDM4 and KDM5 subfamilies were identified. Subsequently, a C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-one series was designed to rationally exploit these residue differences between the histone substrate binding sites in order to improve affinity for the KDM4-subfamily over KDM5-subfamily enzymes. In particular, residues E169 and V313 (KDM4A numbering) were targeted. Additionally, conformational restriction of the flexible pyridopyrimidinone C8-substituent was investigated. These approaches yielded potent and cell-penetrant dual KDM4/5-subfamily inhibitors including >19a (KDM4A and KDM5B Ki = 0.004 and 0.007 μM, respectively). Compound cellular profiling in two orthogonal target engagement assays revealed a significant reduction from biochemical to cell-based activity across multiple analogues; this decrease was shown to be consistent with 2OG competition, and suggests that sub-nanomolar biochemical potency will be required with C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-one compounds to achieve sub-micromolar target inhibition in cells.
机译:鉴定出在KDM4和KDM5亚家族之间不同的组蛋白底物结合位点上的残基。随后,设计了一个C8取代的吡啶并[3,4-d]嘧啶-4(3H)-系列,以合理利用组蛋白底物结合位点之间的这些残基差异,以提高对KDM4-亚家族的亲和力。亚家族酶。特别地,残基E169和V313(KDM4A编号)被靶向。另外,研究了柔性吡啶并嘧啶酮C8-取代基的构象限制。这些方法产生了包括> 19a (分别为KDM4A和KDM5B Ki = 0.004和0.007μM)的有效和细胞渗透性双重KDM4 / 5-亚家族抑制剂。在两个正交的靶标参与试验中进行的复合细胞分析显示,多种类似物从生化活性到基于细胞的活性均显着降低。该下降表明与2OG竞争一致,并表明C8取代的吡啶并[3,4-d]嘧啶4(3H)-一种化合物需要亚纳摩尔的生化能力才能实现亚微摩尔靶标抑制在细胞中。

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号